- Home
- MCN vs UNCY Comparison
MCN vs UNCY Comparison
Compare MCN & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MCN | UNCY |
|---|---|---|
| Founded | 2004 | 2016 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.6M | 141.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MCN | UNCY |
|---|---|---|
| Price | $6.07 | $6.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $44.50 |
| AVG Volume (30 Days) | 78.3K | ★ 484.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 9.96% | N/A |
| EPS Growth | N/A | ★ 56.25 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $675,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.16 | $0.45 |
| 52 Week High | $6.40 | $7.57 |
Technical Indicators
Market Signals| Indicator | MCN | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 48.51 | 54.80 |
| Support Level | $6.03 | $5.90 |
| Resistance Level | $6.18 | $6.82 |
| Average True Range (ATR) | 0.08 | 0.35 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 35.90 | 77.57 |
Price Performance
Historical ComparisonAbout MCN Madison Covered Call & Equity Strategy Fund
XAI Madison Equity Premium Income Fund is an investment management company. The Fund invests in an actively managed equity portfolio comprised of individual stocks and covered call options. The Fund's primary investment objective is to provide high level of current income and gains, with a secondary objective of capital appreciation.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.